At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
RhIGF-1drug
Likely dose
RhIGF-1 40 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents
In Brief
A Phase 2 clinical trial evaluating RhIGF-1 for Anorexia Nervosa. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The purpose of this study was to determine whether giving insulin like growth factor-I (IGF-I) to adolescent low weight girls is safe and whether this increases levels of bone formation markers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnorexia Nervosa
CountriesUnited States
CollaboratorsTercica
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedAug 2007
Primary CompletionMay 2008
Study CompletionDec 2008
TodayJul 2026
First PostedAug 15, 2007
Enrollment StartMar 1, 2007
Primary CompletionMay 1, 2008
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.9 years ago
Interventions
RhIGF-1drug
35-40 mcg/k/dose twice daily SC